How many drugs treat Bulimia nervosa?

Drug Landscape tracks 2 marketed treatments for Bulimia nervosa (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bulimia-nervosa.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bulimia nervosa — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bulimia nervosa (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bulimia nervosa, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Prozac	fluoxetine	Eli Lilly and Company	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter		1987-12-29
Prozac	Prozac	RenJi Hospital		Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Eli Lilly and Company · 1 drug in Bulimia nervosa
RenJi Hospital · 1 drug in Bulimia nervosa

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bulimia nervosa:

Cite this brief

Drug Landscape (2026). Bulimia nervosa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bulimia-nervosa. Accessed 2026-06-10.

Bulimia nervosa full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing